Synairgen Supercharges R&D With $100m Financing
To Support COVID-19 Study Of Inhaled Beta-Interferon
Executive Summary
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
You may also be interested in...
Synairgen Aims To Disprove Doubts About Interferon Therapy In COVID-19
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study
UK Biotech Defies Pandemic, On Course For Record Fundraising Year
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
GSK’s Emma Walmsley Made A Dame In UK Honors
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.